Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Morgan Stanley raised Accenture Plc (NYSE:ACN) price target from $271 to $320. Morgan Stanley analyst James Faucette upgraded the stock from Equal-Weight to Overweight. Accenture shares closed at $274.66 on Monday. See how other analysts view this stock.
- Wedbush increased the price target for Tyra Biosciences Inc (NASDAQ:TYRA) from $30 to $37. Wedbush analyst Robert Driscoll maintained an Outperform rating. Tyra Biosciences shares closed at $22.12 on Monday. See how other analysts view this stock.
- Chardan Capital raised Palvella Therapeutics Inc (NASDAQ:PVLA) price target from $110 to $174. Chardan Capital analyst Geulah Livshits maintained a Buy rating. Palvella Therapeutics shares closed at $88.98 on Monday. See how other analysts view this stock.
- Cantor Fitzgerald boosted the price target for Microchip Technology Inc (NASDAQ:MCHP) from $65 to $85. Cantor Fitzgerald analyst C.J. Muse upgraded the stock from Neutral to Overweight. Microchip Technology shares closed at $67.18 on Monday. See how other analysts view this stock.
- Needham raised the price target for SI-Bone Inc (NASDAQ:SIBN) from $24 to $27. Needham analyst David Saxon maintained a Buy rating. SI-Bone shares closed at $18.41 on Monday. See how other analysts view this stock.
- Goldman Sachs increased Rockwell Automation Inc (NYSE:ROK) price target from $329 to $448. Goldman Sachs analyst Joe Ritchie upgraded the stock from Sell to Neutral. Rockwell Automation shares settled at $401.65 on Monday. See how other analysts view this stock.
- Baird cut Dentsply Sirona Inc (NASDAQ:XRAY) price target from $14 to $12. Baird analyst Jeffrey Johnson maintained a Neutral rating. Dentsply Sirona shares closed at $11.40 on Monday. See how other analysts view this stock.
- Baird raised Tandem Diabetes Care Inc (NASDAQ:TNDM) price target from $18 to $30. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. Tandem Diabetes Care shares closed at $22.11 on Monday. See how other analysts view this stock.
- Citizens increased the price target for Abivax SA (NASDAQ:ABVX) from $114 to $131. Citizens analyst Jason Butler maintained a Market Outperform rating. Abivax shares settled at $117.91 on Monday. See how other analysts view this stock.
- Jefferies boosted Federal Realty Investment Trust (NYSE:FRT) price target from $101 to $115. Jefferies analyst Linda Tsai upgraded the stock from Hold to Buy. Federal Realty Investment Trust shares closed at $100.91 on Monday. See how other analysts view this stock.
Considering buying ACN stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
ACNAccenture PLC
$280.101.98%
FRTFederal Realty Investment Trust
$101.800.88%
MCHPMicrochip Technology Inc
$68.511.98%
PVLAPalvella Therapeutics Inc
$88.74-0.27%
ROKRockwell Automation Inc
$404.460.70%
SIBNSI-BONE Inc
$18.500.49%
TNDMTandem Diabetes Care Inc
$23.335.52%
TYRATyra Biosciences Inc
$22.07-0.23%
XRAYDentsply Sirona Inc
$11.40-%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

